IBI-334
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IBI-334, covering 2026-01-06 to 2026-01-06. Get the full timeline:
Most recent: Clinical Trial Update: The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. [Phase 1, Phase 2]